Build vs Buy — Alternative Protein

What this means for Alternative Protein

• Taste parity is still the dominant adoption barrier — even loyal early adopters hit a sensory ceiling, and the broader category cannot grow until taste matches conventional protein at the same price point.
• Scaling cost is brutal — bioreactor capex, growth media costs, and yield curves for cultivated meat are far from cost parity with conventional meat, and the timeline to parity keeps slipping.
• Regulatory pathway is fragmented — FDA-then-USDA for cultivated meat in the US, EFSA novel foods in Europe, with most countries still establishing frameworks.

Where it pays to act

• AI for ingredient and formulation discovery — generative chemistry, taste-prediction models, and high-throughput screening to compress the R&D cycle for new formulations.
• AI for fermentation and bioprocess optimization — yield prediction, contamination detection, and run-condition optimization that lift bioreactor economics.